Breaking News

Collaboration efforts result in two new diagnostic lab partners – NSW Health Pathology in Sidney, Australia and CHU de Reims in France

Details

Our Mission

EpiSign™ is dedicated to revolutionizing the diagnosis and understanding of rare diseases through our advanced epigenetic diagnostic technology.

Our mission is to bridge the gap in rare disease diagnostics by offering precise, efficient and comprehensive genomic and epigenomic analysis.

By harnessing the power of DNA methylation episignatures, we aim to significantly reduce the diagnostic odyssey for individuals with rare diseases, facilitating timely and accurate diagnoses that can lead to better-personalized care and treatments.

Our approach is grounded in the belief that through cutting-edge research, collaboration and innovation, we can unlock the full potential of clinical epigenomics to enhance patient outcomes and provide hope to millions of individuals and their families facing the challenges of rare diseases.

Our Vision

At EpiSign™, we envision a world where the diagnosis of rare diseases is no longer a lengthy, complex process, but an accessible and swift journey towards understanding and intervention.

Our vision is to be at the forefront of clinical genomics and epigenomics, setting new standards for the diagnosis and treatment of rare diseases worldwide.

We strive to expand our EpiSign™ technology to encompass a broader spectrum of disorders, including those caused by environmental exposures and beyond, becoming a global beacon of hope for the rare disease community.

Through continuous innovation, research and collaboration, we aim to unlock the mysteries of the epigenome, providing invaluable insights into disease mechanisms and paving the way for novel therapeutic approaches.

Our goal is to transform the landscape of rare disease diagnostics, ensuring that every individual has access to precise, personalized healthcare solutions that empower them to lead healthier, fuller lives.